Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Assets Average (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Assets Average for 3 consecutive years, with $58.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 37.13% to $58.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $58.1 million, a 37.13% decrease, with the full-year FY2024 number at $71.4 million, down 0.71% from a year prior.
  • Assets Average was $58.1 million for Q3 2025 at Mereo BioPharma, down from $65.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $212.0 million in Q3 2023 to a low of $58.1 million in Q3 2025.
  • A 3-year average of $93.2 million and a median of $76.0 million in 2024 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: plummeted 56.39% in 2024, then increased 18.19% in 2025.
  • Mereo BioPharma's Assets Average stood at $118.5 million in 2023, then tumbled by 30.3% to $82.6 million in 2024, then dropped by 29.61% to $58.1 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Assets Average are $58.1 million (Q3 2025), $65.5 million (Q2 2025), and $72.4 million (Q1 2025).